Medulloblastoma, WNT-activated, is a molecularly defined subgroup of medulloblastoma characterized by activation of the WNT/beta-catenin signaling pathway, typically through somatic CTNNB1 (beta-catenin) exon 3 mutations or germline APC mutations. This subgroup represents approximately 10% of medulloblastomas and has the most favorable prognosis of all molecular subgroups, with >95% long-term survival. WNT-activated tumors arise from lower rhombic lip progenitors, have classic histology, and are characterized by nuclear beta-catenin accumulation, monosomy 6, and expression of WNT target genes including DKK1 and AXIN2. Treatment de-escalation trials are exploring reduced-intensity therapy to minimize long-term toxicity.
Ask a research question about Medulloblastoma, WNT-Activated. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Medulloblastoma, WNT-Activated
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-05-09T19:42:12Z'
description: >-
Medulloblastoma, WNT-activated, is a molecularly defined subgroup of medulloblastoma
characterized by activation of the WNT/beta-catenin signaling pathway, typically
through somatic CTNNB1 (beta-catenin) exon 3 mutations or germline APC mutations.
This subgroup represents approximately 10% of medulloblastomas and has the most
favorable prognosis of all molecular subgroups, with >95% long-term survival.
WNT-activated tumors arise from lower rhombic lip progenitors, have classic
histology, and are characterized by nuclear beta-catenin accumulation, monosomy
6,
and expression of WNT target genes including DKK1 and AXIN2. Treatment de-escalation
trials are exploring reduced-intensity therapy to minimize long-term toxicity.
categories:
- Central Nervous System Neoplasm
- Pediatric Brain Tumor
- Molecularly Defined Tumor
- Embryonal Tumor
parents:
- medulloblastoma
has_subtypes:
- name: WNT-Activated Medulloblastoma with CTNNB1 Mutation
description: >-
The most common form, with somatic activating mutations in CTNNB1 exon 3
that prevent beta-catenin phosphorylation and degradation. Sporadic, not
associated with germline predisposition.
- name: WNT-Activated Medulloblastoma with APC Mutation
description: >-
Associated with Turcot syndrome (APC germline mutation). APC normally
promotes beta-catenin degradation; loss leads to WNT pathway activation.
Patients require genetic counseling and screening for colorectal polyposis.
pathophysiology:
- name: WNT/Beta-Catenin Pathway Activation
description: >-
Activating mutations in CTNNB1 (beta-catenin) prevent phosphorylation at
serine/threonine residues in exon 3, blocking proteasomal degradation. This
leads to nuclear accumulation of beta-catenin, which complexes with TCF/LEF
transcription factors to activate WNT target genes.
evidence:
- reference: PMID:40967259
reference_title: "Evolving Biology and Therapy of WNT-Activated Medulloblastoma."
supports: SUPPORT
snippet: "nearly all cases harbor either somatic CTNNB1 mutations or germline APC mutations."
explanation: This abstract sentence supports that WNT-activated medulloblastomas are driven by CTNNB1 or APC mutations.
cell_types:
- preferred_term: cerebellar granule cell
term:
id: CL:0001031
label: cerebellar granule cell
biological_processes:
- preferred_term: Wnt signaling pathway
modifier: INCREASED
term:
id: GO:0016055
label: Wnt signaling pathway
locations:
- preferred_term: cerebellum
term:
id: UBERON:0002037
label: cerebellum
downstream:
- target: Nuclear Beta-Catenin Accumulation
description: Stabilized beta-catenin translocates to nucleus
- name: Nuclear Beta-Catenin Accumulation
description: >-
Stabilized beta-catenin accumulates in the nucleus where it acts as a
transcriptional coactivator with TCF/LEF family transcription factors.
Nuclear beta-catenin immunostaining is a diagnostic hallmark of WNT-activated
medulloblastoma.
biological_processes:
- preferred_term: canonical Wnt signaling pathway
modifier: INCREASED
term:
id: GO:0060070
label: canonical Wnt signaling pathway
downstream:
- target: WNT Target Gene Activation
description: Beta-catenin/TCF complex activates transcription of WNT targets
- name: WNT Target Gene Activation
description: >-
Nuclear beta-catenin/TCF complexes drive expression of WNT target genes
including MYC, CCND1 (cyclin D1), AXIN2, and DKK1. These genes promote
proliferation and can serve as biomarkers of WNT pathway activation.
biological_processes:
- preferred_term: positive regulation of gene expression
modifier: INCREASED
term:
id: GO:0010628
label: positive regulation of gene expression
downstream:
- target: Cell Proliferation and Tumor Formation
description: WNT target genes drive proliferation of cerebellar progenitors
- name: Cell Proliferation and Tumor Formation
description: >-
WNT pathway activation drives proliferation of cerebellar progenitor cells,
likely from the lower rhombic lip region. Despite constitutive pathway
activation, these tumors have favorable biology, possibly due to their
differentiation state or immunological features.
cell_types:
- preferred_term: cerebellar granule cell
term:
id: CL:0001031
label: cerebellar granule cell
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
histopathology:
- name: Malignant Pediatric Brain Tumor
finding_term:
preferred_term: Medulloblastoma
term:
id: NCIT:C3222
label: Medulloblastoma
frequency: VERY_FREQUENT
description: Medulloblastoma is the most common malignant brain tumor of childhood.
evidence:
- reference: PMID:41544627
reference_title: "Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma."
supports: SUPPORT
snippet: "Medulloblastoma, the most common malignant brain tumor of childhood, exhibits"
explanation: Abstract states medulloblastoma is the most common malignant brain tumor of childhood.
phenotypes:
- category: Neurological
name: Headache
frequency: VERY_FREQUENT
description: >-
Headache from increased intracranial pressure due to obstructive hydrocephalus.
Often worse in morning and may be accompanied by vomiting.
phenotype_term:
preferred_term: Headache
term:
id: HP:0002315
label: Headache
- category: Neurological
name: Ataxia
frequency: VERY_FREQUENT
description: >-
Cerebellar ataxia with truncal instability and gait disturbance from tumor
involvement of cerebellar structures.
phenotype_term:
preferred_term: Ataxia
term:
id: HP:0001251
label: Ataxia
- category: Neurological
name: Nausea and Vomiting
frequency: VERY_FREQUENT
description: >-
Vomiting, often in the morning, from increased intracranial pressure and
brainstem involvement.
phenotype_term:
preferred_term: Vomiting
term:
id: HP:0002013
label: Vomiting
- category: Neurological
name: Papilledema
frequency: FREQUENT
description: >-
Optic disc swelling from increased intracranial pressure. May lead to
visual symptoms if prolonged.
phenotype_term:
preferred_term: Papilledema
term:
id: HP:0001085
label: Papilledema
genetic:
- name: CTNNB1
association: Somatic Mutation
notes: >-
CTNNB1 exon 3 mutations are present in approximately 85-90% of WNT-activated
medulloblastomas. Mutations occur at serine/threonine phosphorylation sites
(codons 33, 37, 41, 45), preventing APC/Axin-mediated degradation.
evidence:
- reference: PMID:33405951
reference_title: "Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)."
supports: SUPPORT
snippet: "Mutations in CTNNB1 (96%), DDX3X (37%), and SMARCA4 (24%) were most common in WNT tumors"
explanation: Documents the high frequency of CTNNB1 mutations (96%) in WNT-activated medulloblastoma from the SJMB03 international phase III trial.
- name: APC
association: Germline/Somatic Mutation
notes: >-
APC mutations occur in approximately 10-15% of WNT-activated medulloblastomas.
Germline APC mutations cause Turcot syndrome (familial adenomatous polyposis
with CNS tumors). Somatic APC mutations also occur.
- name: DDX3X
association: Somatic Mutation
notes: >-
DDX3X mutations occur in approximately 50% of WNT-activated medulloblastomas.
DDX3X encodes an RNA helicase that may cooperate with WNT signaling in
tumorigenesis.
evidence:
- reference: PMID:22820256
reference_title: "Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations."
supports: SUPPORT
snippet: "Recurrent somatic mutations were newly identified in an RNA helicase gene, DDX3X, often concurrent with CTNNB1 mutations"
explanation: Original exome sequencing study identifying DDX3X as recurrently mutated in medulloblastoma, often concurrent with CTNNB1 mutations in WNT tumors.
- reference: PMID:33405951
reference_title: "Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)."
supports: SUPPORT
snippet: "Mutations in CTNNB1 (96%), DDX3X (37%), and SMARCA4 (24%) were most common in WNT tumors"
explanation: Documents the frequency of DDX3X mutations (37%) in WNT-activated medulloblastoma from the SJMB03 trial.
- name: SMARCA4
association: Somatic Mutation
notes: >-
SMARCA4 mutations occur in approximately 25% of WNT-activated medulloblastomas.
Encodes a SWI/SNF chromatin remodeling complex component.
evidence:
- reference: PMID:33405951
reference_title: "Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)."
supports: SUPPORT
snippet: "Mutations in CTNNB1 (96%), DDX3X (37%), and SMARCA4 (24%) were most common in WNT tumors"
explanation: Documents the frequency of SMARCA4 mutations (24%) in WNT-activated medulloblastoma from the SJMB03 trial.
- name: TP53
association: Somatic Mutation
notes: >-
TP53 mutations are rare in WNT-activated medulloblastoma (approximately 5%),
in contrast to SHH-activated tumors where they confer worse prognosis.
- name: Monosomy 6
association: Chromosomal Alteration
notes: >-
Monosomy 6 is present in approximately 85% of WNT-activated medulloblastomas
and is a useful cytogenetic marker for this subgroup. The mechanism by which
it contributes to tumorigenesis is unclear.
evidence:
- reference: PMID:17172831
reference_title: "Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis."
supports: SUPPORT
snippet: "loss of chromosome 6 was exclusively observed in Wnt/Wg-active tumors, but not in Wnt/Wg-negative cases (8/13 vs. 0/19; p = 0.0001)"
explanation: Early molecular study demonstrating exclusive association of chromosome 6 loss with WNT pathway-active medulloblastomas.
- reference: PMID:21267586
reference_title: "Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups."
supports: SUPPORT
snippet: "Monosomy 6 was strongly associated with WNT tumors"
explanation: Confirms strong association of monosomy 6 with WNT molecular subgroup.
treatments:
- name: Surgical Resection
description: >-
Maximal safe resection is first-line treatment. Near-total or gross total
resection is achieved in most cases. Complete resection associated with
excellent outcomes.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
- name: Craniospinal Irradiation
description: >-
Craniospinal irradiation (CSI) is standard for medulloblastoma due to risk
of leptomeningeal dissemination. Treatment de-escalation trials are exploring
reduced-dose CSI (18-23.4 Gy vs standard 23.4-36 Gy) for WNT-activated tumors
given excellent prognosis.
treatment_term:
preferred_term: radiation therapy
term:
id: MAXO:0000014
label: radiation therapy
evidence:
- reference: PMID:32743560
reference_title: "Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma."
supports: SUPPORT
snippet: "Over the past decade, wingless-activated (WNT) medulloblastoma has been identified as a candidate for therapy de-escalation based on excellent survival"
explanation: Supports the rationale for radiation de-escalation trials in WNT-activated medulloblastoma due to excellent survival.
- name: Chemotherapy
description: >-
Multi-agent chemotherapy (cisplatin, vincristine, cyclophosphamide, lomustine)
is standard. De-escalation trials are exploring reduced-intensity or
chemotherapy-omitting regimens for WNT-activated tumors to minimize
long-term toxicity while maintaining excellent survival.
treatment_term:
preferred_term: chemotherapy
term:
id: MAXO:0000647
label: chemotherapy
evidence:
- reference: PMID:32743560
reference_title: "Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma."
supports: SUPPORT
snippet: "Maintenance chemotherapy is identified as a strong predictor of relapse, with individuals receiving high doses of cyclophosphamide or ifosphamide having only one very late molecularly confirmed relapse"
explanation: Documents the role of maintenance chemotherapy with cyclophosphamide in preventing relapse in WNT-activated medulloblastoma.
notes: >-
WNT-activated medulloblastoma has the best prognosis of all molecular subgroups
with >95% 5-year survival. This excellent outcome has led to treatment
de-escalation trials (e.g., SJMB12, ACNS1422) exploring reduced radiation and
chemotherapy to minimize late effects including neurocognitive dysfunction,
endocrine deficiencies, hearing loss, and secondary malignancies while
maintaining cure rates.
disease_term:
preferred_term: medulloblastoma WNT activated
term:
id: MONDO:0850196
label: medulloblastoma WNT activated
classifications:
icdo_morphology:
classification_value: Embryonal Neoplasm
harrisons_chapter:
- classification_value: cancer
- classification_value: solid tumor
references:
- reference: DOI:10.1007/s11910-023-01316-9
title: Recent Advances in Pediatric Medulloblastoma
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: of Review Review recent advances in the understanding of pediatric medulloblastoma including etiology, biology, radiology, and management of pediatric medulloblastoma.
supporting_text: of Review Review recent advances in the understanding of pediatric medulloblastoma including etiology, biology, radiology, and management of pediatric medulloblastoma.
evidence:
- reference: DOI:10.1007/s11910-023-01316-9
reference_title: Recent Advances in Pediatric Medulloblastoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: of Review Review recent advances in the understanding of pediatric medulloblastoma including etiology, biology, radiology, and management of pediatric medulloblastoma.
explanation: Deep research cited this publication as relevant literature for Medulloblastoma WNT Activated.
- reference: DOI:10.1080/14737175.2018.1503536
title: Clinical and pre-clinical utility of genomics in medulloblastoma
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: Clinical and pre-clinical utility of genomics in medulloblastoma
supporting_text: Clinical and pre-clinical utility of genomics in medulloblastoma
- reference: DOI:10.1111/nan.12945
title: WNT‐activated, <i>MYC</i> ‐amplified medulloblastoma displaying intratumoural heterogeneity
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: WNT‐activated, <i>MYC</i> ‐amplified medulloblastoma displaying intratumoural heterogeneity
supporting_text: WNT‐activated, <i>MYC</i> ‐amplified medulloblastoma displaying intratumoural heterogeneity
- reference: DOI:10.11588/heidok.00034239
title: 'ITCC-P4: Molecular characterization and multi-omics analysis of pediatric patient tumor and Patient-Derived Xenograft (PDX) models for preclinical model selection'
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: 'ITCC-P4: Molecular characterization and multi-omics analysis of pediatric patient tumor and Patient-Derived Xenograft (PDX) models for preclinical model selection'
supporting_text: 'ITCC-P4: Molecular characterization and multi-omics analysis of pediatric patient tumor and Patient-Derived Xenograft (PDX) models for preclinical model selection'
- reference: DOI:10.18632/oncotarget.28360
title: 'WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?'
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: 'WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?'
supporting_text: 'WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?'
- reference: DOI:10.21203/rs.3.rs-5332503/v1
title: Implementation of methylation profiling of central nervous system tumors at largest public health center in Brazil
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: Tumor entities of the Central Nervous System (CNS) are defined by the WHO classification and range from benign neoplasms to highly malignant tumors.
supporting_text: Tumor entities of the Central Nervous System (CNS) are defined by the WHO classification and range from benign neoplasms to highly malignant tumors.
evidence:
- reference: DOI:10.21203/rs.3.rs-5332503/v1
reference_title: Implementation of methylation profiling of central nervous system tumors at largest public health center in Brazil
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Tumor entities of the Central Nervous System (CNS) are defined by the WHO classification and range from benign neoplasms to highly malignant tumors.
explanation: Deep research cited this publication as relevant literature for Medulloblastoma WNT Activated.
- reference: DOI:10.24976/discov.med.202335178.69
title: Comparative Analysis of the Embryonal Brain Tumors Based on Their Molecular Features
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: Comparative Analysis of the Embryonal Brain Tumors Based on Their Molecular Features
supporting_text: Comparative Analysis of the Embryonal Brain Tumors Based on Their Molecular Features
- reference: DOI:10.3389/fonc.2023.1237170
title: High frequency of WNT-activated medulloblastomas with CTNNB1 wild type suggests a higher proportion of hereditary cases in a Latin-Iberian population
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: Medulloblastomas are the most common primary malignant brain tumors in children.
supporting_text: Medulloblastomas are the most common primary malignant brain tumors in children.
evidence:
- reference: DOI:10.3389/fonc.2023.1237170
reference_title: High frequency of WNT-activated medulloblastomas with CTNNB1 wild type suggests a higher proportion of hereditary cases in a Latin-Iberian population
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Medulloblastomas are the most common primary malignant brain tumors in children.
explanation: Deep research cited this publication as relevant literature for Medulloblastoma WNT Activated.
- reference: DOI:10.3390/biology12050729
title: 'Wnt Signaling in Brain Tumors: A Challenging Therapeutic Target'
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: The involvement of Wnt signaling in normal tissue homeostasis and disease has been widely demonstrated over the last 20 years.
supporting_text: The involvement of Wnt signaling in normal tissue homeostasis and disease has been widely demonstrated over the last 20 years.
evidence:
- reference: DOI:10.3390/biology12050729
reference_title: 'Wnt Signaling in Brain Tumors: A Challenging Therapeutic Target'
supports: SUPPORT
evidence_source: OTHER
snippet: The involvement of Wnt signaling in normal tissue homeostasis and disease has been widely demonstrated over the last 20 years.
explanation: Deep research cited this publication as relevant literature for Medulloblastoma WNT Activated.
- reference: DOI:10.3390/cancers15153889
title: 'The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined Therapies'
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: Medulloblastoma is the most common malignant pediatric brain tumor and is associated with significant morbidity and mortality in the pediatric population.
supporting_text: Medulloblastoma is the most common malignant pediatric brain tumor and is associated with significant morbidity and mortality in the pediatric population.
evidence:
- reference: DOI:10.3390/cancers15153889
reference_title: 'The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined Therapies'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Medulloblastoma is the most common malignant pediatric brain tumor and is associated with significant morbidity and mortality in the pediatric population.
explanation: Deep research cited this publication as relevant literature for Medulloblastoma WNT Activated.
- reference: DOI:10.3390/cancers16203530
title: Risk-Stratified Radiotherapy in Pediatric Cancer
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: While the cure rate of cancer in children has markedly improved in the last few decades, late effects continue to be a problem in survivors.
supporting_text: While the cure rate of cancer in children has markedly improved in the last few decades, late effects continue to be a problem in survivors.
evidence:
- reference: DOI:10.3390/cancers16203530
reference_title: Risk-Stratified Radiotherapy in Pediatric Cancer
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: While the cure rate of cancer in children has markedly improved in the last few decades, late effects continue to be a problem in survivors.
explanation: Deep research cited this publication as relevant literature for Medulloblastoma WNT Activated.
- reference: DOI:10.3390/diagnostics13111915
title: 'Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?'
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: Medulloblastomas, highly aggressive neoplasms of the central nervous system (CNS) that present significant heterogeneity in clinical presentation, disease course, and treatment outcomes, are common in childhood.
supporting_text: Medulloblastomas, highly aggressive neoplasms of the central nervous system (CNS) that present significant heterogeneity in clinical presentation, disease course, and treatment outcomes, are common in childhood.
evidence:
- reference: DOI:10.3390/diagnostics13111915
reference_title: 'Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Medulloblastomas, highly aggressive neoplasms of the central nervous system (CNS) that present significant heterogeneity in clinical presentation, disease course, and treatment outcomes, are common in childhood.
explanation: Deep research cited this publication as relevant literature for Medulloblastoma WNT Activated.
- reference: DOI:10.3390/diagnostics13142398
title: 'Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment'
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: Medulloblastoma is the most common malignant brain tumor in children.
supporting_text: Medulloblastoma is the most common malignant brain tumor in children.
evidence:
- reference: DOI:10.3390/diagnostics13142398
reference_title: 'Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Medulloblastoma is the most common malignant brain tumor in children.
explanation: Deep research cited this publication as relevant literature for Medulloblastoma WNT Activated.
- reference: DOI:10.3390/diagnostics14040358
title: Clinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings:
- statement: Clinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma
supporting_text: Medulloblastoma (MB) comprises four broad molecular subgroups, namely wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4, respectively, with subgroup-specific developmental origins, unique genetic profiles, distinct clinico-demographic characteristics, and diverse clinical outcomes.
evidence:
- reference: DOI:10.3390/diagnostics14040358
reference_title: Clinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Medulloblastoma (MB) comprises four broad molecular subgroups, namely wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4, respectively, with subgroup-specific developmental origins, unique genetic profiles, distinct clinico-demographic characteristics, and diverse clinical outcomes.
explanation: Deep research cited this publication as relevant literature for Medulloblastoma WNT Activated.
- reference: DOI:10.1016/j.xcrm.2020.100038
title: Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma
found_in:
- Medulloblastoma_WNT_Activated-deep-research-falcon.md
findings: []
WNT-activated medulloblastoma is a molecularly defined medulloblastoma entity characterized by activation of the canonical WNT/β-catenin pathway, most commonly through CTNNB1 exon 3 hotspot mutations with resultant nuclear β-catenin accumulation; it comprises roughly ~10% of medulloblastomas overall. (moreno2023highfrequencyof pages 2-3, shcherbina2023comparativeanalysisof pages 2-4)
Typical location is midline/central posterior fossa around the fourth ventricle, with potential extension toward the cerebellar peduncle/brainstem; neuroradiology often shows diffusion restriction and typical posterior fossa mass effects. (jackson2023recentadvancesin pages 1-2, rechberger2023exploringthemolecular pages 1-2, shcherbina2023comparativeanalysisof pages 2-4)
Note on ICD/MeSH/OMIM/Orphanet/MONDO: Specific numeric identifiers were not present in the retrieved texts; therefore they cannot be reported with citations from this tool run.
The disease concept and frequencies are derived from aggregated disease-level resources (reviews/cohort series) and multi-institutional clinical cohorts, not from EHR-only individual patient sources. (nobre2020patternofrelapse pages 1-3, moreno2023highfrequencyof pages 2-3, shcherbina2023comparativeanalysisof pages 2-4)
Direct abstract quote (molecular definition): Moreno et al. state that WNT-activated medulloblastomas are “usually caused by mutations in the CTNNB1 gene (85%–90%), and most remaining cases of CTNNB1 wild type are thought to be caused by germline mutations in APC.” (Frontiers in Oncology; Sep 2023; https://doi.org/10.3389/fonc.2023.1237170) (moreno2023highfrequencyof pages 2-3)
Direct abstract quote (genetic counseling implication): The same 2023 study concludes: “Considering that CTNNB1 wild-type cases may exhibit APC germline mutations, our study suggests a higher incidence (~30%) of hereditary WNT-activated medulloblastomas in the Latin-Iberian population.” (Frontiers in Oncology; Sep 2023; https://doi.org/10.3389/fonc.2023.1237170) (moreno2023highfrequencyof pages 2-3)
No protective environmental factors or gene–environment interaction evidence specific to WNT-MB was identified in the retrieved sources.
Posterior fossa medulloblastoma commonly presents with: - Headache and vomiting consistent with raised intracranial pressure (often worse on awakening, progressive). (jackson2023recentadvancesin pages 1-2) - Ataxia/gait instability due to cerebellar dysfunction (particularly midline vermian involvement). (jackson2023recentadvancesin pages 1-2) - In infants/very young children: macrocephaly, fussiness, decreased oral intake (non-localizing symptoms). (jackson2023recentadvancesin pages 1-2)
Dissemination at diagnosis across medulloblastoma overall is reported around ~20–25% (not WNT-specific), while WNT-MB cohorts often show low metastatic rates at diagnosis (e.g., “very rare <5%” in one cohort table). (jackson2023recentadvancesin pages 1-2, mani2024clinicoradiologicaloutcomesin pages 1-2)
WNT-MB is described as centrally located near midline posterior fossa/fourth ventricle with potential extension into peduncle/brainstem. (shcherbina2023comparativeanalysisof pages 2-4, rechberger2023exploringthemolecular pages 1-2)
Long-term survivorship issues remain a major challenge in pediatric medulloblastoma, and high-dose craniospinal irradiation is emphasized as associated with long-term neurocognitive harm, motivating de-intensification trials in WNT-MB. (jackson2023recentadvancesin pages 1-2, slika2023theneurodevelopmentaland pages 7-8)
A 2024 WNT cohort report explicitly notes that absence of recorded neurocognitive and late-effect data prevents direct assessment of QoL impact in that series (highlighting a common real-world data gap). (mani2024clinicoradiologicaloutcomesin pages 11-12)
Two WNT subtypes are described: - WNT-α: younger/pediatric, enriched for monosomy 6. (mani2024clinicoradiologicaloutcomesin pages 10-11, slika2023theneurodevelopmentaland pages 2-4) - WNT-β: older/adult-leaning, less monosomy 6, sometimes worse prognosis in adult contexts. (mani2024clinicoradiologicaloutcomesin pages 10-11, slika2023theneurodevelopmentaland pages 2-4)
ACMG/AMP classifications and population allele frequencies (gnomAD) were not available in the retrieved evidence.
WNT-MB is part of modern methylation-based CNS tumor classification, and real-world clinical workflows use EPIC methylation arrays and online classifiers to support WHO-recognized diagnoses (including WNT-MB). (green2024wnt‐activatedmyc‐amplifiedmedulloblastoma pages 2-3, wolff2024implementationofmethylation pages 5-8)
A causal chain supported by the retrieved literature: 1. CTNNB1 exon 3 stabilization mutation (or APC loss in predisposition) → 2. β-catenin accumulation and nuclear translocation → 3. Transcriptional activation of WNT-responsive programs supporting tumorigenesis and defining subgroup biology. (moreno2023highfrequencyof pages 2-3, ntenti2023clinicalhistologicaland pages 4-5)
WNT-MB is proposed to arise from lower rhombic lip / pontine mossy-fiber precursor–related lineages in the dorsal brainstem region (extracerebellar origin), consistent with GEMM data and subgroup developmental mapping. (slika2023theneurodevelopmentaland pages 2-4, manfreda2023wntsignalingin pages 11-12)
WNT-MB is linked to distinctive vasculature and a locally disrupted blood–brain barrier, which has been proposed to facilitate chemotherapy penetration and contribute to favorable outcomes. (slika2023theneurodevelopmentaland pages 7-8, nor2018clinicalandpreclinical pages 20-24)
Given proposed rhombic lip/pontine precursor origins: - Neural progenitor cell — CL:0000673 - Neuron — CL:0000540 (tumor cells show neuronal-like differentiation states in subgroup analyses) (slika2023theneurodevelopmentaland pages 2-4)
WNT-MB typically affects older children/adolescents (median ~11–12 years), is rare in infants, and comprises a minority of adult medulloblastomas (~10–15% of adult MB in one review summary). (shcherbina2023comparativeanalysisof pages 2-4, mani2024clinicoradiologicaloutcomesin pages 1-2)
WNT-MB is typically ~10% of medulloblastomas, though cohort composition varies; a Latin-Iberian multi-institution series reported 15% (40/266) WNT-activated tumors. (moreno2023highfrequencyof pages 2-3, moreno2023highfrequencyof pages 1-2)
Most cases are sporadic, but CTNNB1-wildtype WNT-MB has an important association with germline APC (FAP/Turcot), motivating genetic counseling and testing. (moreno2023highfrequencyof pages 2-3)
Relapses are uncommon but frequently metastatic; in the 93-patient cohort, 12/15 relapses were metastatic, with a distinctive tendency to involve the lateral ventricles (8/12 metastatic relapses). Outcomes after relapse were poor with limited salvage, and relapse risk was strongly influenced by the maintenance chemotherapy regimen (higher cumulative cyclophosphamide/ifosfamide exposure associated with fewer relapses). (nobre2020patternofrelapse pages 1-3)
Medulloblastomas typically arise near the superior fourth ventricle/inferior medullary velum region, frequently show diffusion restriction, and may show heterogeneous enhancement/cysts/necrosis on MRI. (jackson2023recentadvancesin pages 1-2)
A pragmatic diagnostic strategy supported by the retrieved sources: 1. CTNNB1 testing (e.g., Sanger sequencing) because exon 3 mutations define most WNT-MB. (moreno2023highfrequencyof pages 2-3) 2. β-catenin IHC (nuclear positivity) as an accessible diagnostic marker and eligibility screen for WNT-directed trials. (jackson2023recentadvancesin pages 1-2, NCT02724579a chunk 2) 3. DNA methylation profiling (Illumina EPIC arrays → MolecularNeuropathology.org/DKFZ classifier) to confirm subgroup and generate CNV plots; multiple real-world implementations show feasibility and typical classifier confidence thresholds. - A 2024 case report illustrates EPIC-based methylation classification for WNT-MB with discussion of confidence scores (≥0.9 strongly supporting a WHO-recognized class; an example case had 0.78, highlighting heterogeneity and need for orthogonal confirmation). (green2024wnt‐activatedmyc‐amplifiedmedulloblastoma pages 2-3) - A 2024 implementation study in Brazil used EPIC arrays and MolecularNeuropathology.org classifiers, with diagnostic agreement in 94% and classifier scores ≥0.9 in ~81% of cases, showing operational feasibility in a public health center workflow. (Preprint; Nov 2024; https://doi.org/10.21203/rs.3.rs-5332503/v1) (wolff2024implementationofmethylation pages 5-8) 4. Germline APC testing is recommended when WNT-MB is CTNNB1-wildtype. (moreno2023highfrequencyof pages 2-3)
Contemporary WNT-MB management is typically maximal safe resection followed by risk-stratified craniospinal irradiation (CSI) + boost and multi-agent chemotherapy, achieving high cure rates but with substantial late toxicity concerns. (mani2024clinicoradiologicaloutcomesin pages 11-12, slika2023theneurodevelopmentaland pages 7-8)
MAXO suggestions (for KB mapping; representative): - Surgical resection — MAXO:0000114 - Craniospinal irradiation — (radiotherapy action term) - Combination chemotherapy — (chemotherapy action term) - Audiology monitoring — (monitoring/assessment term) - Endocrine function monitoring — (monitoring/assessment term)
Because WNT-MB has excellent outcomes, multiple efforts seek to reduce CSI dose and/or chemotherapy intensity to improve long-term quality of survival. (mani2023wntpathwaymedulloblastomawhat pages 2-4, upadhyay2024riskstratifiedradiotherapyin pages 4-5)
However, early attempts at more aggressive de-intensification have been unsafe: - A 2023 review notes that two prospective de-intensification strategies (including omission of upfront CSI) were terminated early due to “unacceptably high relapse rates,” supporting the conclusion that CSI remains integral to curative therapy. (mani2023wntpathwaymedulloblastomawhat pages 1-2) - A 2024 review summary describes a pilot omission-of-CSI approach as inferior, with rapid relapses requiring salvage CSI (reported as all relapsing within <1 year in that summary). (upadhyay2024riskstratifiedradiotherapyin pages 4-5)
URL: https://clinicaltrials.gov/study/NCT02724579
SIOP PNET5 — NCT02066220 (start 2014; status ACTIVE_NOT_RECRUITING)
URL: https://clinicaltrials.gov/study/NCT02066220
St. Jude SJMB12 — NCT01878617 (start 2013; status ACTIVE_NOT_RECRUITING)
URL: https://clinicaltrials.gov/study/NCT01878617
FOR-WNT2 — NCT04474964 (start 2020; status RECRUITING)
Relapse in WNT-MB is influenced by maintenance chemotherapy intensity; in a 93-patient cohort, higher cumulative cyclophosphamide/ifosfamide exposure correlated with fewer relapses, implying that safe radiotherapy reduction must be co-designed with adequate systemic therapy. (nobre2020patternofrelapse pages 1-3)
No established primary prevention strategies exist for sporadic WNT-MB based on the retrieved evidence.
For hereditary predisposition (APC/FAP/Turcot-associated WNT-MB), the actionable prevention-oriented steps in this context are: - Genetic counseling and germline APC testing when WNT-MB is CTNNB1-wildtype (and/or in the presence of family history consistent with FAP). (moreno2023highfrequencyof pages 2-3)
WNT-MB GEMMs typically require stabilized Ctnnb1 (exon-3) activation plus cooperating lesions; Ctnnb1 activation alone is insufficient in some systems. - A cited GEMM: Blbp-Cre; Ctnnb1lox(ex3); Trp53flox/+ produces WNT medulloblastoma with ~15% penetrance and ~290-day latency; adding Pik3caE545K increases penetrance and shortens latency (reported as 100% penetrance within ~3 months in one summary). (nor2018clinicalandpreclinical pages 20-24, manfreda2023wntsignalingin pages 11-12)
PDX repositories include medulloblastoma lines characterized by integrated genomics, though available PDX collections can be biased toward Group 3/MYC-amplified tumors; nonetheless, PDX systems remain a key translational platform for subgroup-specific therapy testing. (nor2018clinicalandpreclinical pages 16-20)
A 2024 ITCC-P4 framework emphasizes using multiple in vivo models (xenografts and/or transgenic models), orthotopic designs when possible, and reporting PK/PD plus biomarker-linked endpoints to support clinical translation—principles directly applicable to WNT-MB preclinical work. (gopisetty2024itccp4molecularcharacterization pages 70-72)
| Domain | Key finding | Specific details | Key citations |
|---|---|---|---|
| Definition / entity | WNT-activated medulloblastoma is a molecularly defined WHO medulloblastoma subgroup with canonical WNT/β-catenin pathway activation | Represents a distinct molecular subgroup recognized in modern WHO CNS classification; often associated with classic histology and favorable-risk biology; integrated diagnosis relies on molecular features rather than histology alone | (mani2024clinicoradiologicaloutcomesin pages 1-2, rechberger2023exploringthemolecular pages 1-2) |
| Core diagnostic markers | Nuclear β-catenin and CTNNB1 alteration are core diagnostic clues | Pathognomonic/characteristic nuclear β-catenin immunostaining is widely used; most tumors harbor CTNNB1 exon 3 hotspot mutations that stabilize β-catenin; methylation profiling can support subgroup assignment in equivocal cases | (moreno2023highfrequencyof pages 2-3, green2024wnt‐activatedmyc‐amplifiedmedulloblastoma pages 2-3, jackson2023recentadvancesin pages 1-2) |
| Molecular alteration | CTNNB1 exon 3 mutation | Reported in ~85–90% of WNT tumors; exon 3 mutations impair β-catenin phosphorylation/degradation, causing nuclear accumulation and WNT pathway activation | (moreno2023highfrequencyof pages 2-3, ntenti2023clinicalhistologicaland pages 4-5, shcherbina2023comparativeanalysisof pages 2-4) |
| Molecular alteration | APC germline variants in CTNNB1-wild-type WNT medulloblastoma | Roughly 10–15% of WNT tumors are CTNNB1-wild-type and many of these are associated with germline APC pathogenic variants/FAP-Turcot syndrome; germline APC testing is recommended in CTNNB1-wild-type cases | (moreno2023highfrequencyof pages 2-3, moreno2023highfrequencyof pages 1-2) |
| Molecular alteration | Monosomy 6 | A hallmark copy-number feature, especially common in pediatric WNT-α; frequency is often >85% in WNT-α and lower in WNT-β/adult cases; useful supportive CNV marker but not universal | (mani2024clinicoradiologicaloutcomesin pages 10-11, slika2023theneurodevelopmentaland pages 2-4, shcherbina2023comparativeanalysisof pages 2-4) |
| Molecular alteration | DDX3X alteration | Recurrently altered in WNT medulloblastoma; reported frequency around ~50% in some summaries/cohorts; included among candidate driver genes | (shcherbina2023comparativeanalysisof pages 2-4, slika2023theneurodevelopmentaland pages 2-4) |
| Molecular alteration | SMARCA4 alteration | Recurrent but less common than CTNNB1/DDX3X; reported around ~26% in one review summary and included among recurrent WNT-associated drivers | (shcherbina2023comparativeanalysisof pages 2-4, slika2023theneurodevelopmentaland pages 2-4) |
| Epidemiology | Share of all medulloblastoma | Usually ~10% of all medulloblastomas; one Latin-Iberian cohort reported 15% (40/266), illustrating population variability | (moreno2023highfrequencyof pages 2-3, mani2024clinicoradiologicaloutcomesin pages 1-2, moreno2023highfrequencyof pages 1-2) |
| Epidemiology | Age distribution / peak | Typically affects older children and adolescents; median age ~10–12 years (reported median 11–12 in several sources); rare in infants; adult WNT cases occur but are less common and may align with WNT-β biology | (shcherbina2023comparativeanalysisof pages 2-4, mani2024clinicoradiologicaloutcomesin pages 1-2, slika2023theneurodevelopmentaland pages 2-4) |
| Epidemiology | Sex distribution | Often described as near-equal sex distribution overall, though individual institutional cohorts may show male predominance | (shcherbina2023comparativeanalysisof pages 2-4, slika2023theneurodevelopmentaland pages 2-4, mani2024clinicoradiologicaloutcomesin pages 1-2) |
| Prognosis | Overall prognostic category | Best-prognosis medulloblastoma subgroup under standard multimodality therapy, with 5-year survival generally >90% in pediatric series | (moreno2023highfrequencyof pages 2-3, upadhyay2024riskstratifiedradiotherapyin pages 4-5, slika2023theneurodevelopmentaland pages 7-8) |
| Prognosis statistic | Single-center 2024 WNT cohort | Median follow-up 72 months; 5-year PFS 87.7% and 5-year OS 91.2% in 61 evaluable molecularly confirmed WNT cases treated with surgery + risk-stratified radio(chemo)therapy | (mani2024clinicoradiologicaloutcomesin pages 1-2) |
| Prognosis statistic | International relapse-pattern cohort | In 93 molecularly confirmed WNT cases, 5-year PFS was 0.84 (84%); 15 relapses occurred, underscoring that prognosis is excellent but relapse is not negligible | (nobre2020patternofrelapse pages 1-3) |
| Prognosis statistic | Published molecularly informed trials/cohorts summarized in 2024 review | Reported examples include HIT2000 nonmetastatic WNT 5-year EFS/OS 100%/100%, SJMB-03 100%/100%, SIOP PNET-4 ~91%/95%, and COG ACNS0331 ~93.3%/95.5% | (mani2024clinicoradiologicaloutcomesin pages 11-12) |
| Relapse pattern | Frequency and distribution | Relapse is uncommon but clinically important; most relapses in the international cohort were metastatic (12/15), with a distinctive tendency for lateral ventricular involvement (8/12 metastatic relapses) rather than only posterior fossa recurrence | (nobre2020patternofrelapse pages 1-3) |
| Relapse pattern | Timing / salvage | Relapse can be early or very late; post-relapse outcomes are generally poor with limited salvage potential despite the favorable frontline prognosis | (mani2024clinicoradiologicaloutcomesin pages 10-11, nobre2020patternofrelapse pages 1-3) |
| Treatment de-escalation relevance | Why this subgroup is targeted for de-intensification | Excellent frontline survival and concern for late neurocognitive/endocrine/ototoxic effects have motivated reduced-CSI trials, but complete omission of CSI proved unsafe in early pilot efforts | (upadhyay2024riskstratifiedradiotherapyin pages 4-5, mani2023wntpathwaymedulloblastomawhat pages 1-2, mani2024clinicoradiologicaloutcomesin pages 11-12) |
Table: This table condenses the core disease-defining, molecular, epidemiologic, prognostic, and relapse-pattern features of WNT-activated medulloblastoma. It is useful as a quick reference for building a structured disease knowledge base entry with supporting citations.
References
(moreno2023highfrequencyof pages 2-3): Daniel Antunes Moreno, Murilo Bonatelli, Augusto Perazzolo Antoniazzi, Flávia Escremim de Paula, Leticia Ferro Leal, Felipe Antônio de Oliveira Garcia, André Escremim de Paula, Gustavo Ramos Teixeira, Iara Viana Vidigal Santana, Fabiano Saggioro, Luciano Neder, Elvis Terci Valera, Carlos Alberto Scrideli, João Stavale, Suzana Maria Fleury Malheiros, Matheus Lima, Glaucia Noeli Maroso Hajj, Hernan Garcia-Rivello, Silvia Christiansen, Susana Nunes, Maria João Gil-da-Costa, Jorge Pinheiro, Flavia Delgado Martins, Carlos Almeida Junior, Bruna Minniti Mançano, and Rui Manuel Reis. High frequency of wnt-activated medulloblastomas with ctnnb1 wild type suggests a higher proportion of hereditary cases in a latin-iberian population. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1237170, doi:10.3389/fonc.2023.1237170. This article has 9 citations.
(shcherbina2023comparativeanalysisof pages 2-4): Valeriia Shcherbina, Larysa Kovalevska, Eugene Pedachenko, Tetyana Malysheva, and Elena Kashuba. Comparative analysis of the embryonal brain tumors based on their molecular features. Discovery medicine, 35 178:733-749, Oct 2023. URL: https://doi.org/10.24976/discov.med.202335178.69, doi:10.24976/discov.med.202335178.69. This article has 6 citations and is from a peer-reviewed journal.
(jackson2023recentadvancesin pages 1-2): Kasey Jackson and Roger J. Packer. Recent advances in pediatric medulloblastoma. Current Neurology and Neuroscience Reports, 23:841-848, Nov 2023. URL: https://doi.org/10.1007/s11910-023-01316-9, doi:10.1007/s11910-023-01316-9. This article has 41 citations and is from a domain leading peer-reviewed journal.
(rechberger2023exploringthemolecular pages 1-2): Julian S. Rechberger, Stephanie A. Toll, Wouter J. F. Vanbilloen, David J. Daniels, and Soumen Khatua. Exploring the molecular complexity of medulloblastoma: implications for diagnosis and treatment. Diagnostics, 13:2398, Jul 2023. URL: https://doi.org/10.3390/diagnostics13142398, doi:10.3390/diagnostics13142398. This article has 20 citations.
(mani2024clinicoradiologicaloutcomesin pages 1-2): Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Neelam Shirsat, Akash Pawar, Sridhar Epari, Ayushi Sahay, Arpita Sahu, Aliasgar Moiyadi, Maya Prasad, Girish Chinnaswamy, and Tejpal Gupta. Clinico-radiological outcomes in wnt-subgroup medulloblastoma. Diagnostics, 14:358, Feb 2024. URL: https://doi.org/10.3390/diagnostics14040358, doi:10.3390/diagnostics14040358. This article has 5 citations.
(mani2023wntpathwaymedulloblastomawhat pages 2-4): Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Neelam Shirsat, Sridhar Epari, Girish Chinnaswamy, and Tejpal Gupta. Wnt-pathway medulloblastoma: what constitutes low-risk and how low can one go? Oncotarget, 14:105-110, Feb 2023. URL: https://doi.org/10.18632/oncotarget.28360, doi:10.18632/oncotarget.28360. This article has 10 citations.
(NCT02724579a chunk 1): Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma. Children's Oncology Group. 2017. ClinicalTrials.gov Identifier: NCT02724579
(nobre2020patternofrelapse pages 1-3): Liana Nobre, Michal Zapotocky, Sara Khan, Kohei Fukuoka, Adriana Fonseca, Tara McKeown, David Sumerauer, Ales Vicha, Wieslawa A. Grajkowska, Joanna Trubicka, Kay Ka Wai Li, Ho-Keung Ng, Luca Massimi, Ji Yeoun Lee, Seung-Ki Kim, Shayna Zelcer, Alexandre Vasiljevic, Cécile Faure-Conter, Peter Hauser, Boleslaw Lach, Marie-Lise van Veelen-Vincent, Pim J. French, Erwin G. Van Meir, William A. Weiss, Nalin Gupta, Ian F. Pollack, Ronald L. Hamilton, Amulya A. Nageswara Rao, Caterina Giannini, Joshua B. Rubin, Andrew S. Moore, Lola B. Chambless, Rajeev Vibhakar, Young Shin Ra, Maura Massimino, Roger E. McLendon, Helen Wheeler, Massimo Zollo, Veronica Ferruci, Toshihiro Kumabe, Claudia C. Faria, Jaroslav Sterba, Shin Jung, Enrique López-Aguilar, Jaume Mora, Carlos G. Carlotti, James M. Olson, Sarah Leary, Jason Cain, Lenka Krskova, Josef Zamecnik, Cynthia E. Hawkins, Uri Tabori, Annie Huang, Ute Bartels, Paul A. Northcott, Michael D. Taylor, Stephen Yip, Jordan R. Hansford, Eric Bouffet, and Vijay Ramaswamy. Pattern of relapse and treatment response in wnt-activated medulloblastoma. Cell Reports Medicine, 1:100038, Jun 2020. URL: https://doi.org/10.1016/j.xcrm.2020.100038, doi:10.1016/j.xcrm.2020.100038. This article has 52 citations and is from a peer-reviewed journal.
(ntenti2023clinicalhistologicaland pages 4-5): Charikleia Ntenti, Konstantinos Lallas, and Georgios Papazisis. Clinical, histological, and molecular prognostic factors in childhood medulloblastoma: where do we stand? Diagnostics, 13:1915, May 2023. URL: https://doi.org/10.3390/diagnostics13111915, doi:10.3390/diagnostics13111915. This article has 9 citations.
(moreno2023highfrequencyof pages 1-2): Daniel Antunes Moreno, Murilo Bonatelli, Augusto Perazzolo Antoniazzi, Flávia Escremim de Paula, Leticia Ferro Leal, Felipe Antônio de Oliveira Garcia, André Escremim de Paula, Gustavo Ramos Teixeira, Iara Viana Vidigal Santana, Fabiano Saggioro, Luciano Neder, Elvis Terci Valera, Carlos Alberto Scrideli, João Stavale, Suzana Maria Fleury Malheiros, Matheus Lima, Glaucia Noeli Maroso Hajj, Hernan Garcia-Rivello, Silvia Christiansen, Susana Nunes, Maria João Gil-da-Costa, Jorge Pinheiro, Flavia Delgado Martins, Carlos Almeida Junior, Bruna Minniti Mançano, and Rui Manuel Reis. High frequency of wnt-activated medulloblastomas with ctnnb1 wild type suggests a higher proportion of hereditary cases in a latin-iberian population. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1237170, doi:10.3389/fonc.2023.1237170. This article has 9 citations.
(mani2024clinicoradiologicaloutcomesin pages 10-11): Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Neelam Shirsat, Akash Pawar, Sridhar Epari, Ayushi Sahay, Arpita Sahu, Aliasgar Moiyadi, Maya Prasad, Girish Chinnaswamy, and Tejpal Gupta. Clinico-radiological outcomes in wnt-subgroup medulloblastoma. Diagnostics, 14:358, Feb 2024. URL: https://doi.org/10.3390/diagnostics14040358, doi:10.3390/diagnostics14040358. This article has 5 citations.
(slika2023theneurodevelopmentaland pages 7-8): Hasan Slika, Paolo Alimonti, Divyaansh Raj, Chad Caraway, Safwan Alomari, Eric M. Jackson, and Betty Tyler. The neurodevelopmental and molecular landscape of medulloblastoma subgroups: current targets and the potential for combined therapies. Cancers, 15:3889, Jul 2023. URL: https://doi.org/10.3390/cancers15153889, doi:10.3390/cancers15153889. This article has 25 citations.
(mani2024clinicoradiologicaloutcomesin pages 11-12): Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Neelam Shirsat, Akash Pawar, Sridhar Epari, Ayushi Sahay, Arpita Sahu, Aliasgar Moiyadi, Maya Prasad, Girish Chinnaswamy, and Tejpal Gupta. Clinico-radiological outcomes in wnt-subgroup medulloblastoma. Diagnostics, 14:358, Feb 2024. URL: https://doi.org/10.3390/diagnostics14040358, doi:10.3390/diagnostics14040358. This article has 5 citations.
(slika2023theneurodevelopmentaland pages 2-4): Hasan Slika, Paolo Alimonti, Divyaansh Raj, Chad Caraway, Safwan Alomari, Eric M. Jackson, and Betty Tyler. The neurodevelopmental and molecular landscape of medulloblastoma subgroups: current targets and the potential for combined therapies. Cancers, 15:3889, Jul 2023. URL: https://doi.org/10.3390/cancers15153889, doi:10.3390/cancers15153889. This article has 25 citations.
(green2024wnt‐activatedmyc‐amplifiedmedulloblastoma pages 2-3): Sage Green, Travis Hoover, David Doss, Kimberly A Davidow, Andrew W. Walter, Catherine E. Cottrell, and Sidharth Mahapatra. Wnt‐activated, myc‐amplified medulloblastoma displaying intratumoural heterogeneity. Neuropathology and Applied Neurobiology, Jan 2024. URL: https://doi.org/10.1111/nan.12945, doi:10.1111/nan.12945. This article has 6 citations and is from a peer-reviewed journal.
(wolff2024implementationofmethylation pages 5-8): Beatriz Martins Wolff, Yuri Casal, Lucas Liro Vieira, Gleyson Francisco Silva Carvalho, Mariana Ribeiro Costa-Siemann, Rafaela da Silva Mendes, Maria Fernanda Freire Chagas, Lissandro Rolim, Yanca Gasparini, Eder Alencar Moura, Felipe D Almeida Costa, and Leslie Domenici Kulikowski. Implementation of methylation profiling of central nervous system tumors at largest public health center in brazil. Nov 2024. URL: https://doi.org/10.21203/rs.3.rs-5332503/v1, doi:10.21203/rs.3.rs-5332503/v1.
(manfreda2023wntsignalingin pages 11-12): Lorenzo Manfreda, Elena Rampazzo, and Luca Persano. Wnt signaling in brain tumors: a challenging therapeutic target. Biology, 12:729, May 2023. URL: https://doi.org/10.3390/biology12050729, doi:10.3390/biology12050729. This article has 20 citations.
(nor2018clinicalandpreclinical pages 20-24): Carolina Nör and Vijay Ramaswamy. Clinical and pre-clinical utility of genomics in medulloblastoma. Expert Review of Neurotherapeutics, 18:633-647, Jul 2018. URL: https://doi.org/10.1080/14737175.2018.1503536, doi:10.1080/14737175.2018.1503536. This article has 17 citations and is from a peer-reviewed journal.
(upadhyay2024riskstratifiedradiotherapyin pages 4-5): Rituraj Upadhyay and Arnold C. Paulino. Risk-stratified radiotherapy in pediatric cancer. Cancers, 16:3530, Oct 2024. URL: https://doi.org/10.3390/cancers16203530, doi:10.3390/cancers16203530. This article has 2 citations.
(NCT02724579a chunk 2): Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma. Children's Oncology Group. 2017. ClinicalTrials.gov Identifier: NCT02724579
(mani2023wntpathwaymedulloblastomawhat pages 1-2): Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Neelam Shirsat, Sridhar Epari, Girish Chinnaswamy, and Tejpal Gupta. Wnt-pathway medulloblastoma: what constitutes low-risk and how low can one go? Oncotarget, 14:105-110, Feb 2023. URL: https://doi.org/10.18632/oncotarget.28360, doi:10.18632/oncotarget.28360. This article has 10 citations.
(NCT02066220 chunk 1): International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma. Universitätsklinikum Hamburg-Eppendorf. 2014. ClinicalTrials.gov Identifier: NCT02066220
(NCT01878617 chunk 1): A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma. St. Jude Children's Research Hospital. 2013. ClinicalTrials.gov Identifier: NCT01878617
(NCT04474964a chunk 2): Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.. Tata Memorial Centre. 2020. ClinicalTrials.gov Identifier: NCT04474964
(NCT04474964 chunk 1): Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.. Tata Memorial Centre. 2020. ClinicalTrials.gov Identifier: NCT04474964
(nor2018clinicalandpreclinical pages 16-20): Carolina Nör and Vijay Ramaswamy. Clinical and pre-clinical utility of genomics in medulloblastoma. Expert Review of Neurotherapeutics, 18:633-647, Jul 2018. URL: https://doi.org/10.1080/14737175.2018.1503536, doi:10.1080/14737175.2018.1503536. This article has 17 citations and is from a peer-reviewed journal.
(gopisetty2024itccp4molecularcharacterization pages 70-72): Apurva Gopisetty. Itcc-p4: molecular characterization and multi-omics analysis of pediatric patient tumor and patient-derived xenograft (pdx) models for preclinical model selection. Text, Jan 2024. URL: https://doi.org/10.11588/heidok.00034239, doi:10.11588/heidok.00034239. This article has 1 citations and is from a peer-reviewed journal.